The efficacy and safety of two doses of strontium ranelate (1g and 2g per day) versus placebo administered orally for 3 years in the treatment of knee osteoarthritis. A prospective multicentre, international, double-blind, placebo-controlled study.

Trial Profile

The efficacy and safety of two doses of strontium ranelate (1g and 2g per day) versus placebo administered orally for 3 years in the treatment of knee osteoarthritis. A prospective multicentre, international, double-blind, placebo-controlled study.

Completed
Phase of Trial: Phase III

Latest Information Update: 08 Dec 2017

At a glance

  • Drugs Strontium ranelate (Primary)
  • Indications Osteoarthritis
  • Focus Registrational; Therapeutic Use
  • Acronyms POLKA; SEKOIA
  • Sponsors Servier
  • Most Recent Events

    • 05 Apr 2014 Results of an analysis of the placebo arm presented at the 2014 World Congress on Osteoporosis, Osteoarthritis and Musculoskeletal Diseases.
    • 05 Apr 2014 Results for the effect of meniscal extrusion and bone marrow lesions on response to strontium ranelate presented at the 2014 World Congress on Osteoporosis, Osteoarthritis and Musculoskeletal Diseases.
    • 05 Apr 2014 Results for the impact of components of the metabolic syndrome on knee joint space narrowing in placebo-treated patients presented at the 2014 World Congress on Osteoporosis, Osteoarthritis and Musculoskeletal Diseases.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top